Nichetti F et al. also found that high PD-L1 expression (≥50%) was one of the independent predisposing factors of TE during immune checkpoint inhibitor (ICI) treatments in patients with locally advanced or metastatic NSCLC [HR=2.55 (95% CI 1.05-6.19)] (61). The gene discussed is CD274; the disease is non-small cell lung carcinoma.